HanAll Biopharma Email Formats

Biotechnology Research • 12 Bongeunsa-ro 114-gil, Daewoong Building 3F, Korea, Republic of • 21-50 Employees

HanAll Biopharma Email Formats

HanAll Biopharma uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@hanall.com), used 68.8% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@hanall.com	68.8%
{first initial}.{last name}	j.doe@hanall.com	18.8%
{first initial}{last name}	jdoe@hanall.co.kr	6.2%
{first name}	john@hanall.co.kr	6.2%

Key Contacts at HanAll Biopharma

Han-Joo Kim

Member Board Of Directors

Mary Bearkland

Sr. Director Clinical Operations/Acting Program Lead

Kristin Wilborn

Director Of Biostatistics

Soraya Nabila Arifa

Associate Director

Youngju Kim

Director Of Global Research Center

Sung-Wuk Kim

Ceo

Company overview

Headquarters	12 Bongeunsa-ro 114-gil, Daewoong Building 3F, Seoul, Gangam-gu 06170, KR
Phone number	+8220241101
Websites	hanall.com hanall.co.kr
NAICS	541714
Keywords	R&D, Innovation, Novel Biologic Drugs
Founded	1973
Employees	21-50
Socials

About HanAll Biopharma

HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for 50 years. HanAll has also expanded its focus to ophthalmology, immunology, oncology, and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials worldwide for the treatment of autoimmune diseases, including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another key asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

C-Suite

Employees by Department

HanAll Biopharma has 12 employees across 6 departments.

Departments

Number of employees

Funding Data

HanAll Biopharma has never raised funding before.

HanAll Biopharma Tech Stack

Discover the technologies and tools that power HanAll Biopharma's digital infrastructure, from frameworks to analytics platforms.

jQuery CDN

CDN

Polyfill

JavaScript libraries

Slick

JavaScript libraries

Swiper

JavaScript libraries

jQuery UI

JavaScript libraries

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

OpenSSL

Web server extensions

PHP

Programming languages

Locomotive Scroll

JavaScript libraries

Frequently asked questions

HanAll Biopharma is located in 12 Bongeunsa-ro 114-gil, Daewoong Building 3F, KR.

You can reach HanAll Biopharma at +8220241101.

HanAll Biopharma was founded in 1973, making it 53 years old. The company has established itself as a significant player in its industry over this time.

HanAll Biopharma has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at HanAll Biopharma

Han-Joo Kim

Member Board Of Directors

Mary Bearkland

Sr. Director Clinical Operations/Acting Program Lead

Kristin Wilborn

Director Of Biostatistics

Soraya Nabila Arifa

Associate Director

Youngju Kim

Director Of Global Research Center